Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1010 in Healthy Children
NCT07870330Phase 1Recruiting
- Sponsor
- Moderna Inc
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mRNA-1010 in seasonal influenza (3 arms), sponsored by Moderna Inc. Primary endpoints: Solicited Local and Systemic Reactogenicity Adverse Reactions at 7 days, Unsolicited Adverse Events at 28 days and 6 more. Started Oct 2026; status: recruiting.
02
Drugs
mRNA-1010
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT07870330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870330.